The $149 headline held. The 4 mg price rose 34 percent.
The advertised price of the Wegovy pill has not moved. NovoCare's pharmacy page said "starting at $149 per month" when the oral drug launched in January 2026, and it says the same thing today. What moved is the price underneath the headline. On 16 August 2026 this project's dataset recorded $149 as the self-pay price for both the 1.5 mg and the 4 mg dose. An archived fetch of the same page on 1 September 2026, re-checked live on 6 September, shows the 4 mg dose now priced at $199 per month. That is a rise of $50, or 33.6 per cent, at the dose every patient on the standard schedule reaches in their second month. The number in the advertisement stayed still while the number most patients actually pay went up.
This article documents that single change, how it was observed, and what it does and does not prove. It is a factual pricing reference, not medical guidance, and it does not constitute investment or financial advice. If you are trying to work out what a weight loss programme would really cost you, our cost quiz walks through the same dose-by-dose logic for your own situation. DoseTruth is a price-comparison publisher: it is not a pharmacy, not a telehealth provider, and it does not prescribe or dispense any medication.
What does NovoCare's pricing page say today?
As of 6 September 2026, NovoCare's self-pay page prices the Wegovy pill at $149 per month for 1.5 mg, $199 per month for 4 mg, and $299 per month for 9 mg and 25 mg. The page's own footnote reads, verbatim, "Self-pay pricing varies by dose. Patients pay $149 for each month of 1.5 mg, $199 per month for 4 mg and $299 per month for 9 mg and 25 mg. One month defined as 1 bottle of 30 tablets." The marketing banner above that footnote still says "Starting at $149 per month". Both statements are true at once. Only one of them describes what a patient pays beyond their first month.
| Dose | Place in the standard schedule | Self-pay price per month |
|---|---|---|
| 1.5 mg | Month one, starting dose | $149 |
| 4 mg | Month two | $199 |
| 9 mg | Month three | $299 |
| 25 mg | Maintenance, month four onward | $299 |
The dosing schedule in that middle column comes from press coverage of the January launch. Pharmaphorum reported on 5 January 2026 that "the Wegovy pill is taken at a dose of 1.5 mg for the first month, 4 mg for the second, and 9 mg for a third month, followed by the recommended maintenance of 25 mg per day." That description matches the dose ladder on the current NovoCare page. It matters because it tells you exactly who the $199 tier reaches. It reaches everyone who stays on the drug past their first bottle.
What changed between 16 August and 1 September?
One tier changed. On 16 August 2026 this project's manually compiled dataset recorded the NovoCare oral Wegovy offer as $149 per month covering both 1.5 mg and 4 mg, with 9 mg and 25 mg at $299. A re-verification pass on 18 August confirmed the same figures on the official page and noted that the page itself flagged 31 August as the end date for the promotional tier. The archived fetch of 1 September, and the live page on 6 September, show 4 mg at $199. The entry dose, the two top doses, and the headline are all unchanged.
| Dose | 16 August 2026 | 1 September 2026 | Change |
|---|---|---|---|
| 1.5 mg | $149 | $149 | None |
| 4 mg | $149 | $199 | Up $50, or 33.6 per cent |
| 9 mg | $299 | $299 | None |
| 25 mg | $299 | $299 | None |
| Advertised headline | Starting at $149 | Starting at $149 | None |
Put in cash terms, the first four months of the standard schedule cost $896 under the August pricing and $946 now, before any insurance or savings card. A patient who reads only the banner would budget $149 a month and be wrong by month two. The headline price now applies to exactly one month of a treatment designed to run for many.
Was the rise announced in advance?
Yes, and the announced date turned out to be wrong, which is itself worth recording. At launch on 5 January 2026, pharmaphorum reported that the $149 rate covered the 1.5 mg and 4 mg versions and that "the lower price for the 4 mg dose will be temporary, however, with the cost due to rise to $199 after 15th April." Biospace reported the same day that "the out-of-pocket price for oral Wegovy, the company's semaglutide drug for obesity, is set at $149 per month for 1.5-mg and 4-mg doses, with higher 9-mg and 25-mg doses costing $299 per month." Both articles were fetched and read during the research for this piece.
The April deadline evidently slipped. This project observed the $149 rate on 4 mg still live on 16 August and again on 18 August, four months after the reported rise date, with the page by then pointing to 31 August as the cut-off. The rise finally shows in the 1 September archive. So the accurate history is: announced for mid April, extended through the summer, executed at the start of September. We found no official Novo Nordisk statement explaining the extension, and we did not go looking for one beyond the pages cited here, so the reason for the delay is unknown to us.
How were the two observations made, and are they comparable?
They were made by two different methods, and you should weigh them accordingly. The 16 August figure comes from manual research: a human-compiled pricing table built from reading the official page and secondary coverage, recorded in the project's dataset with its sources noted. The 1 September figure comes from an automated archive run: a scripted fetch of novocare.com/pharmacy.html that stored the full HTML with a SHA-256 hash and extracted every dollar amount in context. The 6 September confirmation was a live fetch performed while writing this article.
A manual reading and an automated fetch can disagree for boring reasons, such as a region-specific banner or a rendering difference, without any real price change. Two things give us confidence this change is real. First, the 18 August manual re-check explicitly noted the 31 August expiry printed on the page itself, which predicts exactly the change we then observed. Second, the launch press coverage said the $149 rate on 4 mg was temporary from day one. Prediction, expiry notice, and outcome all line up. We still label the comparison as cross-method rather than like-for-like, because that is what it is.
Does this mean weight loss drug prices are rising across the market?
No, and this article makes no such claim. Exactly one programme was verified end to end here: NovoCare's self-pay pricing for the oral Wegovy pill. The neighbouring tiers on the same page held still, which is evidence against a general reset even within Novo's own shop. The Wegovy pen offer, checked on the same live page, still reads $199 per month for new patients through 31 December 2026, rising to $349 per month afterwards for the standard doses.
Several programmes we track could not be re-verified by the same archive method, because their sites block automated fetching. GoodRx returned an HTTP 403 in the 1 September collection run. Lilly's Foundayo pricing page also returned 403. Hims, Henry, and Found have resisted automated collection throughout this project, so their figures rest on secondary coverage and are excluded from any claim in this article. If any of those moved in the same window, we would not know. One verified repricing is a data point, not a trend.
How strong is the evidence for each claim in this article?
Honestly graded, it is mixed, and the grading is below. The core price facts are strong because they come from the seller's own page, captured and hashed. The historical and interpretive claims are weaker, and we say so rather than rounding them up.
| Claim | Evidence type | Strength |
|---|---|---|
| 4 mg self-pay price is $199 as of 6 September 2026 | Live fetch of the official NovoCare page, matching a hashed archive from 1 September | Strong |
| 4 mg was $149 on 16 August 2026 | Manual project dataset, re-confirmed manually 18 August, consistent with launch press reports | Moderate, single team, manual method |
| $149 covered both 1.5 mg and 4 mg at launch | Two independent trade press reports from 5 January 2026, both fetched this session | Moderate, press tier, but mutually corroborating |
| The rise was pre-announced for mid April and slipped to September | One press report for the April date, project observations for the slip | Weak to moderate, single source on the April date |
| Most patients pass through the 4 mg dose in month two | Press description of the label schedule, consistent with the official page's dose ladder | Moderate, not sourced to the FDA label directly |
| Other programmes did not reprice in the same window | Not checked, sites blocked or out of scope | No claim made |
The weakest link is the April date, which rests on a single trade article. The claim about month two rests on the press description of the schedule rather than on the FDA label document itself, and a careful reader should treat it as the label summary it is. Where we could not verify, we cut the claim rather than soften it.
What should a price-watcher take from this?
The practical lesson is that a "starting at" price is a fact about one tier, not about a programme. The durable way to compare programmes is dose by dose and month by month, which is the method behind the comparison work on our home page and the questions in the quiz. Watch the footnotes, because in this case the footnote announced the change two weeks before it happened while the banner never changed at all. Nothing here is a recommendation to buy, delay, or switch anything, and none of it is investment or financial advice. If you have a documented price observation that contradicts anything above, we want it, and the fastest route is the contact page.
Frequently asked questions
Did the advertised price of the Wegovy pill change?
No. The page said "starting at $149 per month" at launch in January 2026 and still says it on 6 September 2026. The change happened one footnote below, where the 4 mg tier moved from $149 to $199.
Who actually pays the $199 price?
Anyone paying cash for the 4 mg dose, which under the standard schedule described at launch is every patient in their second month. The first month at 1.5 mg is still $149, and months three onward at 9 mg or 25 mg are $299.
Is 34 per cent the exact figure?
The exact rise is 33.6 per cent, from $149 to $199, which rounds to 34. In cash terms it is $50 per month at one dose tier.
Could the August observation simply be wrong?
It is the weaker of the two observations because it was manual, and we flag that openly. It is supported by the launch press coverage, by a second manual check on 18 August, and by the expiry date the page itself displayed, so we consider it reliable but not archive-grade.
Did other GLP-1 programmes raise prices too?
Unknown. Only this one programme was verified by archive fetch. GoodRx and Foundayo blocked the automated collection with HTTP 403 responses, and Hims, Henry, and Found have resisted automated fetching throughout, so no claim is made about them.
Is this medical or financial advice?
No. It is a documented price observation with its methods and weaknesses stated. It does not constitute investment or financial advice, and decisions about medication belong with a prescriber.
Sources
- NovoCare Pharmacy self-pay pricing page, Novo Nordisk, fetched live 6 September 2026 and archived 1 September 2026: novocare.com/pharmacy.html. Seller's own page, primary source for its own prices only.
- Pharmaphorum, "Novo Nordisk launches Wegovy pill at $149 a month", 5 January 2026, fetched this session: pharmaphorum.com. Trade press.
- Biospace, "Novo Unveils Oral Wegovy in the US, With Out-of-Pocket Prices at $149 Per Month", 5 January 2026, fetched this session: biospace.com. Trade press.
- Project price dataset, 16 August 2026 compilation and 18 August re-verification, and archive run of 1 September 2026 with SHA-256 hashed page captures. Internal, available on request via the contact page.